DAVID S. WILKES, MD

Venture Advisor
Dean, University of Virginia, Co-Founder ImmuneWorks, Board of Directors, Baxter International, inc; Fmr Major USAF

Dr. Wilkes currently is a physician-scientist, entrepreneur, administrator and educator.  Currently he serves as dean and as the James Carroll Flippin Professor of Medical Science at the University of Virginia School of Medicine, positions he has held since 2015.  He previously served in positions of increasing responsibility at Indiana University School of Medicine, most recently as the Executive Associate Dean for Research Affairs and as the August M. Watanabe Professor of Medical Research between 2009 and 2015. Dr. Wilkes is the co-founder of ImmuneWorks Inc., a biotechnology start-up company, and has served as its chief scientific officer since 2006. Since 2013, he has served as the National Director of the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation; the nation’s eminent program for developing the careers of underrepresented minority physician-scientists at leading medical schools. In 2020, he was elected to the National Academy of Medicine.

Dr. Wilkes currently serves on the board of directors of Baxter International Inc., a leading global medical products company and on the board of directors of Syneos Health, the only fully integrated biopharmaceutical solutions organization. He also currently serves on the Board of Visitors of the Lewis Katz School of Medicine at Temple University and the Villanova University Board of Trustees. He received his bachelor’s degree in biology from Villanova University, his medical degree from Temple University School of Medicine, and conducted his residency at Temple University Hospital. Dr. Wilkes completed a post-doctoral fellowship in pulmonary and critical care at University of Texas Southwestern Medical Center. Dr. Wilkes is a military veteran, having served three years as a major in the U.S. Air Force Medical Corps for which he received a commendation medal for service.

Pier 70 Ventures